Podcast Episodes

Back to Search
A $10B deal, China trial scrutiny and highlights from ADA 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific mee…

12 hours ago

Short Long
View Episode
The deal before the deal
The deal before the deal

Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple.

In this episode, recorded at Fierce Bio…

2 weeks ago

Short Long
View Episode
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)

In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to exam…

2 weeks, 4 days ago

Short Long
View Episode
Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones
Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones

In this episode of “The Top Line,” recorded on site at Fierce Biotech Week in Boston, Fierce’s Ayla Ellison sits down with Christelle Huguet, Ph.D., …

4 weeks ago

Short Long
View Episode
Why MRD is becoming central to oncology drug development (Sponsored)
Why MRD is becoming central to oncology drug development (Sponsored)

In this sponsored episode of The Top Line, experts from Myriad Genetics join host Stephanie Butler to examine how tumor-informed molecular residual d…

1 month ago

Short Long
View Episode
Behind the headlines of ASCO 2026
Behind the headlines of ASCO 2026

Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of …

1 month ago

Short Long
View Episode
Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)
Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)

High‑risk MDS and AML continue to challenge clinicians, with limited durable responses and few options for older or treatment‑refractory patients. In…

1 month, 1 week ago

Short Long
View Episode
Boston, China and the future of biotech
Boston, China and the future of biotech

Boston remains biotech's most influential hub, but the questions facing the region are increasingly global.

Recorded live at Fierce Biotech Week in B…

1 month, 1 week ago

Short Long
View Episode
Why direct-to-patient is the future of pharma access (Sponsored)
Why direct-to-patient is the future of pharma access (Sponsored)

Direct-to-patient models are no longer an experiment - they're becoming a critical part of the modern prescription journey. In this sponsored episode…

1 month, 1 week ago

Short Long
View Episode
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions

Recorded last week at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with Kristen Fortney, Ph.D., co-founder a…

1 month, 2 weeks ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us